Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients

Fertility and Sterility

Volumn 89, Issue 6, 2008, Pages 1685-1693

  Hompes, Peter G A ^a   Broekmans, Frank J ^b   Hoozemans, Diederik A ^a   Schats, Roel ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Highly purified hMG; ICSI; IVF; pregnancy rate; rFSH

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; FISHER EXACT TEST; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MULTICENTER STUDY; NORMAL HUMAN; OOCYTE; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL SIGNIFICANCE;

ADULT; EMBRYO TRANSFER; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; MATERNAL AGE; MENOTROPINS; OVULATION INDUCTION; PATIENT SELECTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 44449117451     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.05.039     Document Type: Article

References (23)

1. Filicori M., Cognigni G.E., Pocognoli P., Ciampaglia W., and Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab 14 (2003) 267-273
2. Fleming R., Chung C.C., Yates R.W., and Coutts J.R. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod 11 (1996) 1854-1858
3. Gordon U.D., Harrison R.F., Fawzy M., Hennelly B., and Gordon A.C. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 75 (2001) 324-331
4. Westergaard L.G., Laursen S.B., and Andersen C.Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 15 (2000) 1003-1008
5. Balasch J., Miro F., Burzaco I., Casamitjana R., Civico S., Ballesca J.L., et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 10 (1995) 1678-1683
6. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 83 (1998) 1507-1514
7. Van Wely M., Westergaard L.G., Bossuyt P.M., and Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 1 (2003) CD003973
8. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril 78 (2002) 520-528
9. Kobayashi M., Nakano R., and Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the "two-cell, two-gonadotrophin" hypothesis of steroidogenesis in the human ovary. J Endocrinol 126 (1990) 483-488
10. Filicori M., Fazleabas A.T., Huhtaniemi I., Licht P., Rao Ch V., Tesarik J., et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 84 (2005) 275-284
11. Platteau P., Andersen A.N., Balen A., Devroey P., Sorensen P., Helmgaard L., et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod 21 (2006) 1798-1804
12. Wolfenson C., Groisman J., Couto A.S., Hedenfalk M., Cortvrindt R.G., Smitz J.E., et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online 10 (2005) 442-454
13. Stokman P.G., de Leeuw R., van den Wijngaard H.A., Kloosterboer H.J., Vemer H.M., and Sanders A.L. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 60 (1993) 175-178
14. Filicori M., Cognigni G.E., Gamberini E., Parmegiani L., Troilo E., and Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 84 (2005) 394-401
15. Filicori M., Cognigni G.E., Pocognoli P., Tabarelli C., Spettoli D., Taraborrelli S., et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod 17 (2002) 2009-2015
16. Westergaard L.G., Erb K., Laursen S.B., Rex S., and Rasmussen P.E. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril 76 (2001) 543-549
17. Kilani Z., Dakkak A., Ghunaim S., Cognigni G.E., Tabarelli C., Parmegiani L., et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 18 (2003) 1194-1199
18. Arce J.C., Nyboe Andersen A., and Collins J. Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review. Hum Reprod 20 (2005) 1757-1771
19. Andersen A.N., Devroey P., and Arce J.C. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 21 (2006) 3217-3227
20. Platteau P., Smitz J., Albano C., Sorensen P., Arce J.C., and Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 81 (2004) 1401-1404
21. Assou S., Anahory T., Pantesco V., Carrour T.L., Pellestor F., Klein B., et al. The human cumulus-oocyte complex gene-expression profile. Hum Reprod 21 (2006) 1705-1719
22. Weston A.M., Zelinski-Wooten M.B., Hutchison J.S., Stouffer R.L., and Wolf D.P. Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod 11 (1996) 608-613
23. Smitz J., Andersen A.N., Devroey P., Arce J.C., and Merit Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinat FSH in IVF patients. Hum Reprod 22 (2007) 676-687